Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.64 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.64 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.64 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511630 | 0.98 | MAPT (0.71) | MAPTRXFP1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL710419 | 0.94 | HDAC1 (0.69) | MAPTRXFP1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL10100243 | 0.87 | MAPT (0.62) | MAPTRXFP1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL258545 | 0.85 | KEAP1 (0.67) | MAPTRXFP1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL13286585 | 0.84 | MAPT (0.63) | MAPTRXFP1PLAAT3PLAAT5PLAAT2 | |
| 5-Phenylvaleric Acid SCHEMBL503601 | 0.83 | MAPT (0.96) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL10352043 | 0.83 | KEAP1 (0.64) | MAPTRXFP1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4886613 | 0.83 | MAPT (0.73) | MAPTRXFP1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL10095118 | 0.82 | MAPT (0.67) | MAPTRXFP1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL29242652 | 0.82 | CES1 (0.66) | MAPTRXFP1PLAAT3PLAAT5PLAAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685248-B1 | OXIDOREDUCTASE FROM METSCHNIKOWIA ZOBELLII | IEP GMBH (DE) | 2010-06-09 | — | — | EP | claimed |
| US-20260069697-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12496345-B2 | Method of treating cancer | INTENSITY THERAPEUTICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20230338251-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| CN-109370994-B | Carbonyl reductase mutant mut-AcCR (G152L/Y189N) and application and coding gene thereof | 华南理工大学 | 2021-05-14 | — | — | CN | disclosed |
| CN-109370994-B | Carbonyl reductase mutant mut-AcCR (G152L/Y189N) and application and coding gene thereof | 华南理工大学 | 2021-05-14 | — | — | CN | disclosed |
| US-20210077627-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10888618-B2 | Method of treating cancer | INTENSITY THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-2897620-B1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| CN-104884065-B | The method for the treatment of cancer | 强烈治疗剂公司 | 2019-01-01 | — | — | CN | disclosed |
| CN-101391960-A | Method for preparing optically pure 2-hydroxyl-4-aryl-butyric ether | UNIV SHANGHAI JIAOTONG (CN) | 2009-03-25 | — | — | CN | disclosed |
| CN-1958556-A | Method for preparing B-2- hydroxycarboxylate | XIANDAO CHEMISTRY CO LTD SHANG (CN) | 2007-05-09 | — | — | CN | disclosed |
| US-6455705-B1 | DISTILLATION-FREE; CHEMICAL INTERMEDIATES FOR THE PRODUCTION OF ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS | DEGUSSA AKTIENGESELLSCHAFT (DE) | 2002-09-24 | — | — | US | disclosed |
| US-5907044-A | SOLVENT EXTRACTION, CRYSTALLIZATION | DEGUSSA AKTIENGELLSCHAFT (DE) | 1999-05-25 | — | — | US | disclosed |
| US-5616727-A | Process for purifying 1-[N2 -((S)-ethoxycarbonyl)-3-phenylpropyl)-N6 -trifluoroacetyl]-l-lysyl-l-proline (lisinopril (TFA) ethyl ester | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1997-04-01 | — | — | US | disclosed |
| EP-0038343-B1 | SUBSTITUTED CARBOXYLIC CETO-ACIDS, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AND MEDICINAL COMPOSITIONS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1984-12-27 | — | — | EP | disclosed |
| US-4334089-A | HYPOGLYCEMIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT (DE) | 1982-06-08 | — | — | US | disclosed |
| EP-0051077-A1 | Substituted oxocarboxylic acids, process for their preparation, their use and medicines containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-05-12 | — | — | EP | disclosed |
| EP-0038343-A1 | SUBSTITUTED CARBOXYLIC CETO-ACIDS, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AND MEDICINAL COMPOSITIONS CONTAINING THEM. | BYK GULDEN LOMBERG CHEM FAB (DE) | 1981-10-28 | — | — | EP | disclosed |
| WO-1981001285-A1 | SUBSTITUTED CARBOXYLIC CETO-ACIDS,PROCESS FOR THE PREPARATION THEREOF,USE THEREOF AND MEDICINAL COMPOSITIONS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1981-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10888618-B2 | Method of treating cancer | PBK, GZMB, NPC1L1 | MAPT 3903/4885RXFP1 1521/4885PLAAT3 855/4885 |
| US-12496345-B2 | Method of treating cancer | PBK, GZMB, NPC1L1 | MAPT 3903/4885RXFP1 1521/4885PLAAT3 855/4885 |
| US-20210077627-A1 | METHOD OF TREATING CANCER | PBK, GZMB, NPC1L1 | MAPT 3903/4885RXFP1 1521/4885PLAAT3 855/4885 |
| US-20230338251-A1 | METHOD OF TREATING CANCER | PBK, GZMB, NPC1L1 | MAPT 3903/4885RXFP1 1521/4885PLAAT3 855/4885 |
| US-20260069697-A1 | METHOD OF TREATING CANCER | PBK, GZMB, KLRK1 | MAPT 1927/4885RXFP1 1401/4885PLAAT3 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.